| abstract |
The present invention relates to a chimeric antigen receptor (CAR), which is a recombinant chimeric protein capable of changing the direction of immune cell specificity and reactivity toward a selected membrane antigen, and more particularly to a chimeric antigen receptor (CAR) which specifically immunizes an extracellular ligand binding domain to EGFRvIII- , ≪ / RTI > scFv derived from EGFRvIII monoclonal antibodies. TCR KO engineered immune cells provided with such CARs are particularly suitable for the treatment of lung, anal, and polymorphic glioblastoma. |